TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors

Inclusion Criteria

• •Signed written informed consent,
• •Age of 18 to 70 years,
• •Life expectancy of at least 6 month,
• •Ability of subject to understand character and individual consequences of clinical trial,
• •Histologically confirmed locally advanced (stage III or IV), non-metastatic squamous cell carcinoma of oro-, hypopharynx and larynx (T2-4, any N, M0),
• •Oral cavity or oro- , hypopharynx or laynx as the primary tumor site,
• •At least one uni-measurable lesion according to the RECIST criteria, Karnofsky Performances Status \> 70%,
• •Adequate bone marrow function: neutrophils \> 1.5 x 109/L, platelets \> 100 x 109/L, hemoglobin \> 10.0 g/dL,
• •Adequate liver function: Bilirubin \< 1.5 mg/dL, SGOT, SGPT \< 3 x ULN, GGT \< 5 x ULN,
• •Adequate renal function: GFR\> 70 ml/min,
• •Negative serum/urine Beta-HCG test in women of childbearing potential,
• •Women of childbearing potential: willingness to use effective contraceptive method, defined as the concomitant use of either an intrauterine pessary (IUP) or contraceptive pill and in both cases, condoms for the treatment duration and 2 months thereafter. Women of non-childbearing potiential are those who are post-menopausal for at least 1 year or sterilized,
• •Men of procreative potential: willingness for effective prevention of procreation, defined as a use of condoms and a use of either an intrauterine pessary (IUP) or a contraceptive pill by his partner for the treatment duration and 2 months thereafter,
• •Subject's consent to collect blood and/or tumor tissue samples for proteomics and genomics. If a patient does not consent, no samples for proteomics and genomics will be taken. Nonetheles, he/she may be enroled in the study